Pharmacogenomics of antidepressant treatment effects
There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more sober optimism, as we have gone a long way towards the goal of guiding therapeutics based on genomics....[Show more]
|Collections||ANU Research Publications|
|Source:||Dialogues in clinical neuroscience|
|01_Licinio_Pharmacogenomics_of_2011.pdf||2 MB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.